Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer
- 1 November 1994
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 171 (5) , 1193-1198
- https://doi.org/10.1016/0002-9378(94)90131-7
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- HER-2/neu expression: A major prognostic factor in endometrial cancerGynecologic Oncology, 1992
- Prognostic factors in human primary breast cancer: Comparison of c-myc and HER2/neu amplificationThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- What determines the instability of c‐myc proto‐oncogene mRNA?BioEssays, 1992
- Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other NeoplasmsScience, 1990
- Oncogene alterations in endometrial carcinomaGynecologic Oncology, 1990
- DNA Ploidy in Endometrial Carcinoma: Major Objective Prognostic FactorMayo Clinic Proceedings, 1990
- Expression of the p185 encoded by her2 oncogene in normal and transformed human tissuesInternational Journal of Cancer, 1990
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomasInternational Journal of Radiation Oncology*Biology*Physics, 1988
- The neu oncogene encodes an epidermal growth factor receptor-related proteinNature, 1986